NO310058B1 - Anvendelse av en hymenopteravgift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner - Google Patents

Anvendelse av en hymenopteravgift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner Download PDF

Info

Publication number: NO310058B1
Authority: NO; Norway
Prior art keywords: treatment; infections; venom; drug; hymenoptera
Prior art date: 1992-06-24

Application number

NO945031A

Other languages

English (en)

Norwegian (no)

Other versions

NO945031L (no

NO945031D0 (no

Inventor

Michael Hansen

Ole Gyring Nieben

Original Assignee

Michael Hansen

Ole Gyring Nieben

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-06-24

Filing date

1994-12-23

Publication date

2001-05-14

1994-12-23 Application filed by Michael Hansen, Ole Gyring Nieben filed Critical Michael Hansen

1994-12-23 Publication of NO945031L publication Critical patent/NO945031L/no

1994-12-23 Publication of NO945031D0 publication Critical patent/NO945031D0/no

2001-05-14 Publication of NO310058B1 publication Critical patent/NO310058B1/no

Links

238000011282 treatment Methods 0.000 title claims abstract description 31
239000003814 drug Substances 0.000 title claims abstract description 20
208000004449 DNA Virus Infections Diseases 0.000 title claims abstract description 9
238000004519 manufacturing process Methods 0.000 title claims abstract description 9
229940079593 drug Drugs 0.000 title claims description 18
241000257303 Hymenoptera Species 0.000 title claims description 9
229920001184 polypeptide Polymers 0.000 claims abstract description 13
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 13
239000003783 hymenoptera venom Substances 0.000 claims abstract description 8
239000002435 venom Substances 0.000 claims description 16
231100000611 venom Toxicity 0.000 claims description 16
210000001048 venom Anatomy 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
239000003659 bee venom Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
208000036142 Viral infection Diseases 0.000 claims description 8
230000009385 viral infection Effects 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 6
108090000623 proteins and genes Proteins 0.000 claims description 6
239000002578 wasp venom Substances 0.000 claims description 6
230000035876 healing Effects 0.000 claims description 5
230000009467 reduction Effects 0.000 claims description 5
PZEUTLIKVUEDLB-UHFFFAOYSA-N 2-[[[2-[[6-amino-2-[[2-[[6-amino-2-[[2-[[2-[[2-[[2-[[2-[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[6-amino-2-[[2-[[2-[2-[[2-[[2-[(2-aminoacetyl)amino]-3-methylpentanoyl]amino]acetyl]amino]propanoylamino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-4-methylpentanoyl]pyrrolidine-2-carbonyl]amino]propanoylamino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(carbamoylamino)propanoyl]-(3-amino-3-oxopropyl)carbamoyl]amino]pentanediamide Chemical compound CCC(C)C(NC(=O)CN)C(=O)NCC(=O)NC(C)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(CO)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CNC(N)=O)C(=O)N(CCC(N)=O)C(=O)NC(CCC(N)=O)C(N)=O PZEUTLIKVUEDLB-UHFFFAOYSA-N 0.000 claims description 4
241000594310 Randia aculeata Species 0.000 claims description 4
229940066369 honey bee venom Drugs 0.000 claims description 4
230000009885 systemic effect Effects 0.000 claims description 4
206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
208000029433 Herpesviridae infectious disease Diseases 0.000 claims description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
208000009608 Papillomavirus Infections Diseases 0.000 claims description 2
208000010531 varicella zoster infection Diseases 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims 1
238000000034 method Methods 0.000 abstract description 5
239000000243 solution Substances 0.000 description 13
241000124008 Mammalia Species 0.000 description 6
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 6
229960004150 aciclovir Drugs 0.000 description 6
239000013543 active substance Substances 0.000 description 6
208000004898 Herpes Labialis Diseases 0.000 description 4
206010067152 Oral herpes Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
208000001688 Herpes Genitalis Diseases 0.000 description 3
201000004946 genital herpes Diseases 0.000 description 3
231100000614 poison Toxicity 0.000 description 3
239000002574 poison Substances 0.000 description 3
208000006673 asthma Diseases 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
206010015150 Erythema Diseases 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
208000006877 Insect Bites and Stings Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
206010042928 Syringomyelia Diseases 0.000 description 1
241000256834 Vespula vulgaris Species 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000000499 gel Substances 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000002642 intravenous therapy Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000009374 poultry farming Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/855—Proteins from animals other than mammals or birds
- Y10S530/858—Proteins from animals other than mammals or birds insects; venom

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Insects & Arthropods (AREA)
Oncology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO945031A 1992-06-24 1994-12-23 Anvendelse av en hymenopteravgift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner NO310058B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK92828A DK82892D0 (da)	1992-06-24	1992-06-24	Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
PCT/DK1993/000208 WO1994000137A1 (en)	1992-06-24	1993-06-24	Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections

Publications (3)

Publication Number	Publication Date
NO945031L NO945031L (no)	1994-12-23
NO945031D0 NO945031D0 (no)	1994-12-23
NO310058B1 true NO310058B1 (no)	2001-05-14

Family

ID=8098009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO945031A NO310058B1 (no)	1992-06-24	1994-12-23	Anvendelse av en hymenopteravgift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner

Country Status (13)

Country	Link
US (2)	US5827829A (de)
EP (1)	EP0653939B1 (de)
JP (1)	JP3631245B2 (de)
AT (1)	ATE190492T1 (de)
AU (1)	AU4312093A (de)
CA (1)	CA2138793C (de)
DE (1)	DE69328102T2 (de)
DK (2)	DK82892D0 (de)
ES (1)	ES2147200T3 (de)
GR (1)	GR3033698T3 (de)
NO (1)	NO310058B1 (de)
PT (1)	PT653939E (de)
WO (1)	WO1994000137A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU9531698A (en) *	1997-10-15	1999-05-03	Alk A/S	Composition and method for treating an encephalomyelopathic, demyelinating or autoimmune disease
US6372471B1 (en)	1998-10-01	2002-04-16	The Rockefeller University	Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon
US20040081702A1 (en)	2000-04-14	2004-04-29	Kim Christopher M.	Bee venom treatment without the sting
EP2187969A2 (de) *	2007-08-17	2010-05-26	Arcion Therapeutics, Inc.	Hochkonzentrierte formulierungen für lokalanästhesie
WO2010019953A1 (en)	2008-08-15	2010-02-18	Arcion Therapeutics, Inc.	High concentration local anesthetic formulations for treating non-neuropathic pain
CN102988263B (zh) *	2012-12-20	2014-08-20	中国科学院南海海洋研究所	一种具有护唇、美唇功效的蜂毒组合物
KR101596344B1 (ko) *	2013-10-30	2016-02-22	주식회사 청진바이오텍	정제봉독을 이용한 동물의 바이러스성 질환의 예방 및/또는 치료용 조성물
US10232048B1 (en)	2014-11-18	2019-03-19	Divine Api-Logics, LLC	Apitherapy method and composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3856936A (en) *	1973-05-07	1974-12-24	Schuyler Dev Corp	Composition and method for cortisol control
JPS55149214A (en) *	1979-05-10	1980-11-20	Toyama Chem Co Ltd	Medical composition consisting of extract from liquid in bee poison gland
US4822608A (en) *	1987-09-14	1989-04-18	Vespa Laboratories, Inc.	Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom or proteinaceous or polypeptide components thereof
AU640611B2 (en) *	1989-04-13	1993-09-02	Vespa Laboratories, Inc.	Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
AU646652B2 (en) *	1989-12-07	1994-03-03	Gesellschaft Fur Strahlen-und Umweltforschung m.b.H	Method and composition for the treatment of mammalian HIV infection

1992
- 1992-06-24 DK DK92828A patent/DK82892D0/da not_active Application Discontinuation
1993
- 1993-06-24 AU AU43120/93A patent/AU4312093A/en not_active Abandoned
- 1993-06-24 DE DE69328102T patent/DE69328102T2/de not_active Expired - Fee Related
- 1993-06-24 AT AT93912693T patent/ATE190492T1/de not_active IP Right Cessation
- 1993-06-24 ES ES93912693T patent/ES2147200T3/es not_active Expired - Lifetime
- 1993-06-24 JP JP50196594A patent/JP3631245B2/ja not_active Expired - Fee Related
- 1993-06-24 WO PCT/DK1993/000208 patent/WO1994000137A1/en active IP Right Grant
- 1993-06-24 PT PT93912693T patent/PT653939E/pt unknown
- 1993-06-24 CA CA002138793A patent/CA2138793C/en not_active Expired - Fee Related
- 1993-06-24 DK DK93912693T patent/DK0653939T3/da active
- 1993-06-24 EP EP93912693A patent/EP0653939B1/de not_active Expired - Lifetime
1994
- 1994-12-23 NO NO945031A patent/NO310058B1/no unknown
1997
- 1997-01-21 US US08/786,518 patent/US5827829A/en not_active Expired - Fee Related
1998
- 1998-06-22 US US09/102,335 patent/US5958887A/en not_active Expired - Fee Related
2000
- 2000-06-15 GR GR20000401388T patent/GR3033698T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK0653939T3 (da)	2000-08-28
US5827829A (en)	1998-10-27
NO945031L (no)	1994-12-23
ES2147200T3 (es)	2000-09-01
PT653939E (pt)	2000-08-31
DE69328102D1 (de)	2000-04-20
AU4312093A (en)	1994-01-24
DK82892D0 (da)	1992-06-24
ATE190492T1 (de)	2000-04-15
EP0653939B1 (de)	2000-03-15
CA2138793C (en)	2004-03-09
GR3033698T3 (en)	2000-10-31
WO1994000137A1 (en)	1994-01-06
US5958887A (en)	1999-09-28
NO945031D0 (no)	1994-12-23
JPH07508010A (ja)	1995-09-07
JP3631245B2 (ja)	2005-03-23
CA2138793A1 (en)	1994-01-06
DE69328102T2 (de)	2000-11-09
EP0653939A1 (de)	1995-05-24

Publication	Publication Date	Title
Gierer et al.	1956	Infectivity of ribonucleic acid from tobacco mosaic virus
DK173078B1 (da)	1999-12-20	Anvendelse af en lysozym-dimer og/eller en ribonuclease-dimer til fremstilling af et lægemiddel til behandling af virus- el
Erdem et al.	2014	Umbilical cord blood serum therapy for the management of persistent corneal epithelial defects
JPH06172183A (ja)	1994-06-21	医薬組成物
Salamon et al.	1982	Peripheral corneal ulcers, conjunctival ulcers, and scleritis after cataract surgery
NO310058B1 (no)	2001-05-14	Anvendelse av en hymenopteravgift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
EP0772445B1 (de)	2004-03-31	Pharmazeutische präparate, insbesondere ovula, die viele verschiedene aktive bestandteile enthalten
CN112190707A (zh)	2021-01-08	一种抗hpv重组人凝胶及其制备方法
US4049798A (en)	1977-09-20	Method for the treatment of Herpes Simplex
Ho et al.	1975	Kinetics of corneal epithelial regeneration. II. Epidermal growth factor and topical corticosteroids.
Thygeson et al.	1960	The unfavorable effect of topical steroid therapy on herpetic keratitis
Bloomfield et al.	1980	Herpes infections in the immunosuppressed host
ANHALT et al.	1978	Toxic epidermal necrolysis: case report
EA001462B1 (ru)	2001-04-23	Способ профилактики или терапевтического лечения заболевания, связанного с повышенной концентрацией свободных окислительных радикалов в сыворотке крови
JP2001501620A (ja)	2001-02-06	免疫不全ウイルス感染の治療方法
Thygeson	1967	Chronic herpetic keratouveitis
Pierce et al.	1973	Herpes zoster ophthalmicus treated with cytarabine
EP1206267B1 (de)	2004-09-29	Arzneimittel enthaltend xenogene oligo- oder/und polyribonukleotide
Kasbeer et al.	1975	Intravitreal oxacillin in experimental staphylococcal endophthalmitis
RU2434607C1 (ru)	2011-11-27	Способ лечения инфекционных воспалительных заболеваний роговицы
Kaufman	1971	The development of resistance in the eye
Jin et al.	2008	Toxic epidermal necrolysis complicated by Mucor infection.
Chavarria et al.	1966	Treatment of Children with Intestinal Amebiasis Due to Entamoeba Histolytica with a Single Dose of Paromomycin (Humatin®)
Olifirova et al.	2017	Possibilities of therapy optimization of patients with superficial burning wounds
RU2220720C1 (ru)	2004-01-10	Способ профилактики нарушений овариально-менструального цикла и эндокринного бесплодия у женщин репродуктивного возраста с клещевыми нейроинфекциями